Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.

Journal: HIV medicine
PMID: 27093565

Abstract

OBJECTIVES: To compare the efficacy, in current clinical practice, of first regimens containing abacavir with lamivudine (ABC/3TC) or tenofovir with emtricitabine (TDF/FTC) in patients with baseline viral load ≥100,000 HIV-1 RNA copies/mL.

Authors

  • P Flandre
    INSERM, UMR-S 1136, Paris, France.
  • P Pugliese
    Infectious Diseases Department, CHU Archet, Nice, France.
  • C Allavena
    Infectious Diseases Department, CHU Hotel Dieu, Nantes, France.
  • C Katlama
    Pierre Louis Institute of Epidemiology and Public Health, Sorbonne University, UPMC Université de Paris 06, UMR_S 1136, Paris, France.
  • L Cotte
    Infectious Diseases Department, Hospices Civils de Lyon, Lyon, France.
  • A Cheret
    EA 3620, Université Paris-Descartes, Sorbonne Paris Cité, Paris, France.
  • A Cabié
    Infectious Diseases Department, CHU de Martinique, Fort de France, France.
  • D Rey
    Le Trait d'Union, HIV Care Center, CHU Strasbourg, Strasbourg, France.
  • C Chirouze
    UMR CNRS 6249 Chrono-Environnement, Université de Franche-Comté, CHRU Besançon, Besançon, France.
  • F Bani-Sadr
    Reims Champagne-Ardenne University, Faculté de médecine, EA-4684/SFR CAP-SANTE, Reims, France.
  • L Cuzin
    Regional Center for HIV Care and Coordination, INSERM UMR1027, Toulouse 3 University, Toulouse, France.

Keywords

External Resources

Popular Topics
Recent Journals